T 250 - Toyama

Drug Profile

T 250 - Toyama

Latest Information Update: 03 Apr 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Toyama Chemical
  • Class Antiplatelets; Antivirals; Vascular disorder therapies
  • Mechanism of Action GPIIb-IIIa antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Peripheral vascular disorders; Reperfusion injury; Transient ischaemic attacks; Unstable angina pectoris

Most Recent Events

  • 30 May 2001 Profile reviewed but no significant changes made
  • 31 Oct 2000 Phase-I clinical trials for Peripheral vascular disorders in United Kingdom (PO)
  • 31 Oct 2000 Phase-I clinical trials for Reperfusion injury in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top